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Dystroglycan has recently been characterised in blood tissue cells, as part of the dystrophin
glycoprotein complex involved in the differentiation process of neutrophils.
Purpose
In the present study we have investigated the role of dystroglycan in the human promyelo-
cytic leukemic cell line Kasumi-1 differentiated to macrophage-like cells.
Methods
We characterised the pattern expression and subcellular distribution of dystroglycans in
non-differentiated and differentiated Kasumi-1 cells.
Results
Our results demonstrated by WB and flow cytometer assays that during the differentiation
process to macrophages, dystroglycans were down-regulated; these results were con-
firmed with qRT-PCR assays. Additionally, depletion of dystroglycan by RNAi resulted in
altered morphology and reduced properties of differentiated Kasumi-1 cells, including mor-
phology, migration and phagocytic activities although secretion of IL-1β and expression of
markers of differentiation are not altered.
Conclusion
Our findings strongly implicate dystroglycan as a key membrane adhesion protein involved
in actin-based structures during the differentiation process in Kasumi-1 cells.
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Introduction
Hematopoietic stem cells (HSC) are multipotent cells that have the potential to differentiate
into all different blood cell types, whilst retaining HSC potential through numerous cell divi-
sions, by a process named haematopoiesis. Intrinsic and extrinsic cues regulate the behaviour
of HSC and protect them from exhaustion [1,2]. A number of extracellular matrix (ECM) and
cell adhesion proteins have been implicated as having effects on regeneration, differentiation,
attachment and migration, and are important factors in the development and progression of
many types of cancer [3].
Dystroglycan is an important adhesion molecule and signalling scaffold described in several
cell types and tissues and is involved in several disease processes [4]. Dystroglycan (Dg) com-
prises two glycoproteins that are post-translationally cleaved from a single gene. The extracel-
lular peripheral membrane subunit α-dystroglycan (α-Dg) undergoes extensive glycosylations
by including mucin type O-glycosylation, O-mannosylation, and N-glycosylation. A central
mucin-like central region of α-Dg is particularly important for interactions between α-Dg and
extracellular matrix proteins such as agrin, perlecan and laminin [5], whilst its C-terminal
domain interacts noncovalently with the N-terminal extracellular domain of the β-subunit. β-
Dg crosses the membrane, and its cytosolic domain is anchored to actin through the interac-
tion with dystrophin, utrophin and other cytoskeletal linker proteins [4,6].
The Kasumi-1 cell line was derived from the peripheral blood of a 7-year-old Japanese boy
diagnosed as Acute Myeloid Leukaemia (AML) FAB M2 in relapse after bone marrow trans-
plantation and expresses a 8:21 chromosome translocation [7]. The Kasumi-1 cells can differ-
entiate into macrophage-like cells when treated with phorbol ester, 12-
0-tetradecanoylphorbol-13-acetate (TPA) [8].
Recently, we described the role of Dg in HL-60 cells with an active participation in the che-
motaxis, phagocytosis and differentiation process to human neutrophils [9]. In the present
work we describe the pattern expression and subcellular distribution of dystroglycans in differ-
entiated and non-differentiated Kasumi-1 cells. Our results suggest a dynamic traffic in the cel-
lular compartments and differential expression of dystroglycan species, characteristic of cell
linage and its physiological conditions. Additionally we investigated the key role Dg plays in
actin-based structure assembly and differentiation process in macrophage-like cells.
Materials and Methods
Kasumi-1 Cell culture and differentiation
Kasumi-1 cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine
serum, 400 mM L-glutamine, 50 μM gentamycin, 25 mMHEPES, 2 g/L sodium bicarbonate, 1
mM sodium pyruvate in a humid atmosphere of 5% CO2 at 37°C. For differentiation into a
macrophage like cells, Kasumi-1 cells were differentiated (dKasumi-1) with 10−7 M 12-0-tetra-
decanoylphorbol-13-acetate (TPA) for 7 days [7]. Cell viability was assessed by exclusion of
0.2% trypan blue and was routinely>90% before and after differentiation.
Treatment of Kasumi-1 cells with cytoskeleton inhibitor
For morphological analysis, differentiated and non-differentiated Kasumi-1 cells (1 x 105) were
incubated with the same volume of the drug in order to obtain final concentrations of 10 μmol
of Cytochalasin D in DMSO [10] for 60 min at room temperature. Equivalent final amounts of
DMSO were added to control cultures. For differentiation markers, differentiated Kasumi-1
cells (1 x 105) were simultaneously incubated with 10 μmol of Cytochalasin D in DMSO or
DMSO and 10−7 M 12-0-tetradecanoylphorbol-13-acetate (TPA) for 7 days.
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Immunofluorescence staining
Antibodies used: α-dystroglycan clone VIA4-1 monoclonal antibody Cat. no. 05–298, α-dystro-
glycan clone IIH6C4, α-dystroglycan clone 6C1 and GAPDHMAB374 were purchased from
Millipore (Billerica, MA, USA), β-dystroglycan Cat. no. sc-30405 monoclonal antibody Cat. no.
sc-21012, were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), β-dys-
troglycan PY892 Cat. no. 617102 was purchased from Biolegend, (San Diego, CA, USA).
Kasumi-1 cells were adhered to poly-D-lysine-coated coverslips and after 60 minutes per-
meabilised and fixed with a mixture of 2% p-formaldehyde, 0.04% NP40 in the cytoskeleton
stabilizing solution PHEM and triton 0.2%. All the immunofluorescence procedures have been
described before [9].
Morphological analysis
Filopodia size and number were detected using the software FiloDetect from images taken
from fluorescence microscopy [11].
Western blotting analysis
Kasumi-1 cells were resuspended and lysed with a 2X lysis buffer (0.5% NP-40, 2 mMNa3VO4,
PMSF) containing a protease inhibitor cocktail. Homogenates were sonicated 3 times for 15 sec-
onds. The protein concentrations were determined by the BCAmethod. The protein extract was
mixed with loading buffer (Tris–HCl sodium dodecyl sulfate, β-mercaptoethanol, glycerol, bro-
mophenol blue) and boiled for 5 minutes. Whole cell lysates were separated as described in [9].
Plasmids and transfection
shRNA constructs targeting dystroglycan or control shRNA were generated using the RNAi-
Ready pSiren-RetroQ system (Clontech Laboratories Inc. Palo Alto, CA, USA) and have been
described previously [9]. Kasumi-1 cells (2 × 106/ ml) were transfected with 2μg DNAmixed
with 2 μg pEGFP-N1 to mark the shRNA transfected cell population (Clontech Laboratories
Inc. Palo Alto, CA, USA) on the Nucleofector II machine (Amaxa), according to the manufac-
turer's recommendation (Lonza Walkerrsville Inc. Walkersville, MD). Twenty-four hours after
transfection cells were selected for cell sorting (Moflo XDP, Beckman Coulter, Brea, CA, USA).
For functional assays, selected cells were differentiated for 7 d.
Migration assay
The effect of dystroglycan depletion on Kasumi-1 differentiated cells on migration was evalu-
ated using a 12-well Transwell chamber (Corning, Costar Corp Cambridge, MA, USA).
Kasumi-1 differentiated cells were added to the upper chambers and allowed to migrate for 120
min at 37°C in 5% CO2 towards the lower chamber containing 10
−7 LPS. Migrated cells from
lower chamber were centrifuged at 1200 rpm for 5 min, collected at the bottom of the lower
chambers and quantified; the result was expressed as a percentage of cells added to the top of
the plate.
Quantitative real-time PCR
Total RNA was extracted from Kasumi-1 using Trizol Reagent (Life Technologies, Waltham,
MA, USA) according to the manufacturer’s instruction. 100 ng of total RNA was subjected to
real-time PCR performed in triplicate using KAPA SYBR FAST (one step qRT-PCR kit, Kapa
Biosystems, Wilmington, MA, USA) in a final volume of 20 μl. Reactions without a template or
without the reverse transcriptase were used as negative controls as described in [9].
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Analysis of cell-surface antigens by immunofluorescence flow cytometry
1 X 105 cells/ml of transfected and control Kasumi-1 cells differentiated for 7 days were incu-
bated with monoclonal antibody for 30 min at 4°C, washed twice with phosphate-buffered
saline, and suspended for 30 min at 4°C in 100 μl of Alexa 488-conjugated goat anti-rabbit IgG
(Molecular probes Kallestad Laboratories, Inc., Austin, TX) as previously described [9]. Results
were shown as percentages of positive cells for each antigen.
Phagocytosis assays
1 X 105 cells/ml of transfected and control Kasumi-1 cells differentiated for 7 days were allowed
to interact at 37°C with Phalloidin-TRITC-labeled Candida glabrata, as described in [9].
Enzyme-linked immunosorbent assays (ELISAs) for IL-1β
1 X 105 cells/ml of transfected and control Kasumi-1 cells differentiated for 7 days in 12-well
plates (Corning, Costar Corp Cambridge, MA, USA). The cultures were prepared in duplicate
and stimulated either with E. coli LPS at 1 μg/ml, after 24h of incubation the supernatants were
collected and assayed for secreted IL-1β levels. Cytokine levels were measured according to the
manufacturer’s instructions by using the human IL-1β (Enzo Life Sciences Inc; Farmingdale,
NY, USA).
Laminin Overlay Assay
Differentiated and non-differentiated Kasumi-1 cells extracts enriched by WGA affinity chro-
matography, were transferred to a nitrocellulose membrane. The membrane was blocked with
low-fat milk/Laminin-binding buffer (LBB) (19 mM triethanolamine-HCl, 140 mMNaCl,
1mM CaCl2, 1 mMMgCl2, pH7.4) at room temperature and was washed with 3% BSA/LBB.
The blot was incubated with 10 nM laminin (L2020, Sigma-Aldrich, St. Louis, MO, USA) in
3% BSA/LBB at 4°C for>12 h. After washing with 5% skim milk/LBB, the blot was incubated
with anti-laminin (SC-5582, Sta. Cruz, CA, USA) and IIH6C4 antibodies overnight. After
washing with 5% skim milk/LBB, the blot was incubated with the appropriate HRP-conjugated
secondary antibody at room temperature for 1 h. The blot was developed by enhanced
chemiluminiscence.
Cell fractionation
To obtain nuclear extracts, differentiated and non-differentiated cells were washed twice with 2
ml of ice-cold PBS and collected by centrifugation at 1800 rpm for 15 min at 4°C. The cell pellet
was resuspended in buffer A [10mMNaCl, 10 mM Tris–HCl pH 8.0, 3 mMMgCl2, 0.5%
NP40] supplemented with complete 1X (Roche Applied Science, Indianapolis, IN, USA) and
phosphatase inhibitors [2 mM Na3VO4 and 25 mMNaF] and incubated for 1 h on ice. Then,
buffer B [(v/v) buffer A and 0.6M sucrose] was added, the homogenate was incubated for 15
min on ice and transferred to a glass Dounce homogenizer, stroked 40 times with B pestle, and
centrifuged at 6000 rpm for 10 min at 4°C. The supernatant was saved as cytoplasmic extract.
The nuclear pellet was once washed with (v/v) of buffer A and buffer B at 6000 rpm/5 min and
three times at 6000rpm/5 min with buffer C [(v/v) buffer A without NP40 and buffer B]. Nuclei
were recovered with 2X lysis buffer (20 mM Tris–HCl pH 8.0, 1 mMMgCl2, complete 1X, 2
mMNa3VO4 and 25 mMNaF), 1 volume of 4% SDS and 3 volumes of 1X lysis buffer incu-
bated for 1 h at 4°C, and pre-cleared at 13,000 rpm for 2 min at 4°C. The supernatant was
saved as nuclear extract.
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Statistical analysis
Statistical analysis was carried out with GraphPad Prism for Windows ver5 software (Graph-
Pad Software, Inc., La Jolla, CA, USA). Unpaired T-test and One-way Analysis of variance
(ANOVA) were utilized for data analysis.
Results
Dystroglycan is present in Kasumi-1 cells
To determine the pattern expression of dystroglycan (Dg) in differentiated (dKasumi-1 cells)
and non-differentiated Kasumi-1 cells (ndKasumi-1), we performed western blot (WB) assays
using antibodies directed to laminin binding glycans present in α-Dg, antibodies raised against
β-Dg and β-DgPY892. The molecular mass of α-Dg varies from 120 to 200 kDa, depending on
the extent of its glycosylation and tissue source [12].
We detected with VIA4 antibody a prominent protein band of 70 kDa in nd-Kasumi-1 cells
compared with dKasumi-1. Kasumi-1 cells for these assays were cultured in the presence of
decanoyl-RVKR-CMK, a furin inhibitor. Other bands of 62 kDa and 35 kDa were observed
only in ndKasumi-1 cells extracts; bands of higher relative mass were not apparent under this
treatment and with the antibody used. However nd-Kasumi-1 and d-kasumi-1 cell lysates
enriched with WGA showed the presence of the full-length α-Dg of 150 kDa revealed with
IIH6C4 antibody. Densitometric analysis of α-Dg species of 150 kDa and 80 kDa showed that
both were more expressed in Kasumi-1 non-differentiated cells (Fig 1B).
β-Dg was observed with bands of 43 kDa, 38 kDa and a faint band of 31 kDa, these last two
bands were more evident for ndKasumi-1 cells. β-Dg phosphorylated on tyrosine 892 (β-
DgPY892) was revealed by the presence of 50 kDa bands in both samples but was more appar-
ent in nd-Kasumi-1, in contrast a band corresponding to 31 kDa was more evident in d-
Kasumi-1 cells. The presence of bands corresponding to 43 kDa and 35 kDa were equivalent in
Kasumi-1 differentiated and Kasumi-1 non-differentiated cells (Fig 1C).
Relative protein levels showed a statistical significance of α-Dg 150 kDa band with mean
values of 0.2465 and 0.1664 for non-differentiated and differentiated Kasumi-1 cells respec-
tively; and 80 kDa band with values of 0.1709 and 0.0365 for non-differentiated and differenti-
ated Kasumi-1 cells respectively. Relative protein mean values for β-DgPY892 (50 kDa)
corresponded to 0.4555 and (31 kDa) 0.0687 for non-differentiated Kasumi-1; while for differ-
entiated Kasumi-1 cells, relative values expression for 50 k Da and 31 k Da species were 0.2542
and 0.1322 respectively (Fig 1A). Considering the relative protein levels we compared the pro-
portion of β-DgPY892 of 31 kDa in relation to the sum of the different reactive bands detected
with the respective antibody and the mean value registered to the nd-Kasumi-1 cells represent
the half of the mean value observed for d-Kasumi-1 cells (S1 Fig).
To evaluate the subcellular distribution of Dg subunits, double immunofluorescence (IF)
staining and confocal microscopy analysis on differentiated Kasumi-1 (d-Kasumi-1 cells) and
non-differentiated Kasumi-1 cells (nd-Kasumi-1 cells), were performed utilizing antibodies
raised against α-Dg, β-Dg and β-DgPY892 revealed with Alexa-Fluor-488 secondary antibody.
Actin filaments were identified with Tetramethyl rhodamine iso-thiocyanate (TRITC)-phalloi-
din. In nd-Kasumi-1 cells, α-Dg subunit displayed a punctuated pattern distributed mainly at
the plasma membrane where it co-localized with actin filaments. This distribution was very
similar to that observed in differentiated cells, although α-Dg was also observed in the cyto-
plasm. In both d-Kasumi-1 and nd-Kasumi-1 cells, β-Dg was observed with a discrete patched
pattern at the cytoplasm, but in differentiated cells the label was strongly observed in the
nucleus. Apparently most of the β-Dg corresponded to its phosphorylated form, which was
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also increased and mainly located in the nucleus. The relative fluorescence intensities showed
values statistically significant for α-Dg and β-DgPY892 in Kasumi non-differentiated com-
pared to Kasumi-1 differentiated cells (Fig 2B).
To evaluate if there were variations of expression in laminin-binding glycans or α-Dg core
protein during the differentiation process in Kasumi-1 cells, we performed flow cytometry
Fig 1. Pattern expression of dystroglycans in Kasumi-1 cells. Total lysates of differentiated (d-Kasumi-1
cells) and non-differentiated Kasumi-1 cells (nd-Kasumi-1) were analysed by western blot utilizing antibodies
against C-terminal of α-Dg, β-Dg and β-DgPY892. Quantitative analysis using GAPDH as loading control is
shown. Values shown are mean ±SD from three independent experiments (n = 3), respectively. * P<0.05.
doi:10.1371/journal.pone.0144078.g001
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Fig 2. Subcellular distribution of dystroglycans in Kasumi-1 cells. (A) Non-differentiated (nd-Kasumi-1 cells) and differentiated Kasumi-1 cells (d-
Kasumi-1 cells) settled on glass cover slips were processed for double immunofluorescence and analysed by confocal microscopy. Bar = 5μm. (B)
Respective immunofluorescence intensities were quantified. Values shown are mean ±SD from three independent experiments (n = 3), respectively.
***P<0.005. (C) FACS analysis of nd-Kasumi-1 (black boxes) cells showed reduced expression of laminin-binding glycans on α-Dg detected by IIH6C4 and
VIA4, β-Dg and β-DgPY892 compared with d-Kasumi-1 cells (grey boxes). (D) Messenger RNA expression of dystroglycan was examined by quantitative
reverse transcription PCR in control and differentiated Kasumi-1 cells. Values shown are mean ± SD from three independent experiments (n = 3),
respectively. *P<0.05. (nd-Kasumi-1) non-differentiated cells; (d-Kasumi-1) differentiated cells.
doi:10.1371/journal.pone.0144078.g002
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analysis using specific antibodies. Diminished expression not statistically significant of lami-
nin-binding glycans was detected by IIH6C4 antibody for differentiated Kasumi-1, whereas
only a small variation of α-Dg core protein expressed was detected by 6C1 antibody (cranin).
Consistently, a great decrease in the number of laminin-binding glycans was detected by VIA4
antibody in differentiated Kasumi-1 cells. The expression of β-Dg and β-DgPY892 was also
diminished in differentiated Kasumi-1 cells (Fig 2C).
To corroborate the decreased level of expression of dystroglycan subunits in non-differenti-
ated and differentiated states observed by WB, IF and FACS assays, we analysed messenger
RNA (mRNA) expression of d-Kasumi-1 and nd-Kasumi-1 cells by quantitative reverse tran-
scription PCR (RT-qPCR). Fig 2D, shows that mRNA expression of dystroglycans was signifi-
cantly higher in non-differentiated Kasumi-1cells compared to differentiated Kasumi-1 cells
(p<0.05).
Hypoglycosylated α-dystroglycan maintains its laminin-1 binding
properties in differentiated Kasumi-1 cells
To determine if the reduction of α-dystroglycan glycosylation detected by FACS and WB anal-
ysis in dKasumi-1 cells compared to ndKasumi-1 cells affected the ability of α-Dg to bind lami-
nin, we performed a laminin overlay assay using cell extracts enriched by WGA affinity
chromatography. WB with IIH6C4 antibody against the sugar chain moieties of α-DG showed
the corresponding band of 150 kDa, while Laminin-1 was assayed as a control displaying a
band of 400 kDa (Fig 3).
Biochemical fractionation of dystroglycan
To further investigate Dg species observed in different cell compartments of Kasumi-1 cells, we
carried out biochemical fractionation of nucleus and cytoplasm of differentiated and non-dif-
ferentiated Kasumi-1 cells (Fig 4).
Western blots performed at nuclei of non-differentiated Kasumi-1 and differentiated
Kasumi-1 cells extracts revealed bands of 50 kDa, 38 kDa and 30 kDa nuclear dystroglycan,
while the majority of full-length 43 kDa β-Dg was found mainly in the cytoplasmic fraction,
the band of 38 kDa was also abundant in the cytoplasm of nd-Kasumi-1 and d-Kasumi-1 cells.
The use of an antibody specific for β-dystroglycan phosphorylated on Y892, revealed bands of
50 kDa, 43 kDa, and 31 kDa, which were detected, in both cytoplasmic and nuclear fractions of
non-differentiated Kasumi-1 and differentiated Kasumi-1 cells. The phosphorylated 31 kDa
fragment of dystroglycan is the specie more translocated to the nucleus of non-differentiated
cells while the 50 kDa was the more abundant specie at the nucleus of differentiated cells.
Effect of silencing DG on dKasumi-1
Differentiation of Kasumi-1 cells resulted in a decrease in dystroglycan expression (Fig 1). It
was therefore of interest to ascertain whether β-Dg is involved in the physiology of promyelo-
cytic leukaemia cells. In order to test this we analysed how β-Dg depletion influences the differ-
entiation process of Kasumi-1 cells by employing a small interfering RNA (RNAi) to target
dystroglycan (Dg RNAi). The RNAi was co-expressed with GFP to identify unequivocally indi-
vidual RNAi-treated cells. As negative control, RNAi that is predicted not to block the transla-
tion of any specific gene was utilized (control RNAi) [9]. The effectiveness of RNAi treatment
in reducing β-dystroglycan expression in these cells was evaluated by WB and IF assays. Global
immunolabeling of β-Dg was reduced by more than 50% in GFP-expressing cells that co-
express Dg-specific RNAi, compared with control RNAi-treated cells (Fig 5A). These levels of
knockdown are in keeping with studies in other cell lines using the same targeting sequences
Dystroglycan in Kasumi-1 Cells
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[9]. Intensity of the β-dystroglycan immunoreactive band (~43 kDa) was decreased by ~51% in
cell lysates of Kasumi-1 cells transiently transfected with vector expressing Dg RNAi but not in
those expressing the control RNAi (Fig 5B). In parallel with normal macrophages, TPA-differ-
entiated Kasumi-1 cells exhibit vacuole, nuclear lobulation, expression of the cell surface anti-
gen CD68, and phagocytic capability [7] as we confirmed.
To ascertain whether β-dystroglycan depletion affects Kasumi-1 cells, control and β-dystro-
glycan-depleted Kasumi-1 cells (50 X103 cells) were processed for double immunostaining to
detect the presence of morphological changes following differentiation (Fig 6A). The presence of
filopodia was visualized with Filopodia_Code software (Fig 6A, right side, shown in green). β-
Dg-depleted differentiated cells exhibited a significant diminution in the number of filopodia
formed (mean 47 per cell) compared to control differentiated cells that protruded a mean of 94
per cell (Fig 6B), whilst filopodia length was reduced from 20 μm to 15 μm respectively (Fig 6C).
Fig 3. Laminin overlay assay.WGA-purified preparations from differentiated (d-Kasumi-1) and non-
differentiated (nd-Kasumi-1 cells) compartments of Kasumi-1 cells were analysed by laminin overlay assay
andWestern blotting with IIH6C4 and laminin as a control.
doi:10.1371/journal.pone.0144078.g003
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To further confirm if Dg expression affects the differentiation process in Kasumi-1 cells we
monitored in 50 X 103 cells, the expression of CD68, a well-established surface marker for differ-
entiation. There was no difference in CD68 expression in β-dystroglycan-depleted dKasumi-1
cells compared to control dKasumi-1 cells (Fig 6D). To evaluate if Dg down-regulation affected
the ability of cells to produce IL-1β a property related to the activation process, we analysed by
ELISA the secretion of IL-1β of 50 X 103 cells after treatment with LPS. Our results did not show
any difference between the capabilities of macrophage-like cells with Dg depleted compared to
differentiated non-transfected cells (Fig 6E). To test the functional significance of the changes in
number and length of filopodia we performed migration assays in Transwell chamber of 50 X
Fig 4. Cell fractionating andWestern-blotting analysis of dystroglycan. Cellular fractionation of non-
differentiated Kasumi-1 cells (nd-Kasumi-1 cells) and differentiated-Kasumi-1 cells (d-Kasumi-1 cells)
revealed the presence of dystroglycan of 43 kDa and a prominent band of 38 kDa that were observed in the
cytoplasm (C) fraction. This later band was also observed in a lesser extent at the nuclear (N) fraction (upper
panel). For Tyrosine phosphorylated β-dystroglycan (lower panel) the predominant nuclear species was 43
kDa and 50 kDa for nd-Kasumi-1 cells and only a 50 kDa band was observed for dKassumi-1 cells. The 28
kDa fragment remained in the cytoplasmic (C) fraction of both kind of cells. Emerin and calnexin are shown
as nuclear and cytoplasmic markers respectively.
doi:10.1371/journal.pone.0144078.g004
Dystroglycan in Kasumi-1 Cells
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103 cells. Non-transfected differentiated and non-differentiated Kasumi-1 cells were included as
controls. Dg depletion significantly reduced the migration of differentiated Kasumi-1 cells com-
pared to cells treated with RNA control. Dg RNAi halved migration of differentiated Kasumi-1
cells to LPS in relation to the RNA control (Fig 6F). The phagocytic activity was present in 35.6%
of Dg down-regulated differentiated Kasumi-1 cells compared to 57.2% of Dg control in differen-
tiated Kasumi-1 cells. Additional controls of non-differentiated and differentiated non-trans-
fected Kasumi-1 cells showed 6.6% and 48% of phagocytic activity respectively (Fig 6G).
To confirm that β-dg actively participates in actin-based structures and functions we pro-
cessed differentiated Kasumi-1 cells treated with cytochalasin D (CD) an inhibitor of actin poli-
merization. Actin-dependent functions (number and length of filopodia, migration and
phagocytic activity) were affected by actin disorganisation. Number and length of filopidia
diminished with a mean of 72 and 36.5 respectively compared to controls 22 and 14.65 (mean
value) respectively. Cytochalasin D treated cells showed a mean of 7 migrated cells and phagocy-
tosis capability was also diminished to a mean value of 6 cells, compared to controls 67 and 51
respectively. Actin-independent functions (CD68 expression and IL-1β secretion) remained
unaffected. Results of these experiments are shown in Fig 7.
Fig 5. RNAi mediated depletion of β-Dystroglycan in Kasumi-1 cells. (A) Kasumi-1 cells expressing
either control RNAi or Dg RNAi were immunolabeled for β-dystroglycan and analysed for confocal
microscopy. Relative fluorescence units showed a significant depletion of β-Dg. Values shown are mean ±SD
from three independent experiments (n = 3), respectively. **P<0.002. (B) Total Kasumi-1 cells extracts
expressing either control RNAi or Dg RNAi were processed for Western-blot, utilizing an antibody against β-
dystroglycan, corresponding bands were observed at 43 kDa. Densitometry analysis demonstrated β-Dg
knockdown (51%) in cells transfected with a Dg iRNA as compared with cells transfected with a control iRNA.
Values shown are mean ±SD from three independent experiments (n = 3), respectively. * P<0.05.
doi:10.1371/journal.pone.0144078.g005
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Fig 6. β-Dystroglycan-depleted Kasumi-1 cells impairs actin-based structures. (A) Kasumi-1 cells transfected with control and interference vector and
differentiated were analysed by confocal microscopy to evaluate morphological changes in response to knockdown of dystroglycan. (B) The number of
filopodia was quantified by the FiloDetect software in 20 Kasumi-1 RNAi-transfected cells that showed a low number of filopodia in relation to 20 control cells.
Values shown are mean ±SD from three independent experiments (n = 3), respectively. *** P<0.005. (C) The length of filopodia was quantified by the
FiloDetect software in 20 Kasumi-1 RNAi-transfected cells that showed shorter filopodia in relation to 20 control cells. Values shown are mean ±SD from
three independent experiments (n = 3), respectively. * P<0.05. (D) CD68 levels were determined by flow cytometry. Relative CD68 levels obtained in control
RNAi were set at 100%. Values shown are mean ±SD from three independent experiments (n = 3), respectively. (E) The secretion of IL-1βwas measured
and quantified by an ELISA kit of supernatants from control RNAi- or Dg RNAi-treated Kasumi-1 cells. Values shown are mean ±SD from three independent
experiments (n = 3), respectively. (F) The efficiency of migration was measured with a Transwell chamber and Dg-depleted Kasumi-1 cells were less motile
than control cells. Values shown are mean ± SD from three independent experiments (n = 3), respectively. ***P<0.005. (G) Phagocytic ability is lost in Dg
RNAi treated Kasumi-1 cells compared to control Kasumi-1 and non-treated dKasumi-1 cells. Error bars show ±SD, based on a total of three experiments; * =
p<0.05. nd-Kasumi-1 cells:- non-differentiated Kasumi-1 cells; d-Kasumi-1 cells.- differentiated Kasumi-1 cells.
doi:10.1371/journal.pone.0144078.g006
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Fig 7. Cytochalasin D interferes with actin- dependent functions. (A) Differentiated (d-Kasumi-1 cells) and non-differentiated Kasumi-1 cells (nd-Kasumi-
1 cells) treated with cytochalasin D (CD) were analysed by confocal microscopy to evaluate morphological changes in response to actin depolimerization. (B)
The number of filopodia was quantified by the FiloDetect software in 20 Kasumi-1 CD treated cells that showed a low number of filopodia in relation to 20
control cells. Values shown are mean ±SD from three independent experiments (n = 3), respectively. *** P<0.005. (C) The length of filopodia was quantified
by the FiloDetect software in 20 Kasumi-1 CD treated cells that showed shorter filopodia in relation to 20 control cells. Values shown are mean ±SD from
three independent experiments (n = 3), respectively. * P<0.05. (D) CD68 levels were determined by flow cytometry. Relative CD68 levels obtained in control
Kasumi-1 cells were set at 100%. Values shown are mean ±SD from three independent experiments (n = 3), respectively. (E) The secretion of IL-1βwas
measured and quantified by an ELISA kit of supernatants from control and CD-treated Kasumi-1 cells. Values shown are mean ±SD from three independent
experiments (n = 3), respectively. (F) The efficiency of migration was measured with a Transwell chamber and CD treated Kasumi-1 cells were less motile
than control cells. Values shown are mean ± SD from three independent experiments (n = 3), respectively. ***P<0.005. (G) Phagocytic ability is almost lost
in CD treated Kasumi-1 cells compared to control Kasumi-1. Error bars show ±SD, based on a total of three experiments; * = p<0.05. d-Kasumi-1.-
differentiated Kasumi-1 cells; CD.- Cytochalasin D.
doi:10.1371/journal.pone.0144078.g007
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Discussion
We recently demonstrated the subcellular distribution and pattern of expression of Dg in a
promyelocytic cell line HL-60, suggesting the active participation of Dg in granulocytic differ-
entiation [9]. We were interested therefore to investigate whether Dg might have a similar key
role in macrophage-like differentiation. In the present study we characterised the pattern
expression and subcellular distribution of Dg in a human myeloid leukaemia cell line (Kasumi-
1) [7], our results are indicative of Dg role as a scaffold in actin-based structures.
The molecular mass of α-Dg varies from 120 to 180 kDa, depending on the extensive glyco-
slylation, [13]. Using VIA4 and cranin antibodies that poorly recognise higher molecular
weight α-DG species [14], we determined the expression of a prominent band of 80 kDa as
well as bands of 70 kDa and 60 kDa in non-differentiated conditions; but not in differentiated
Kasumi-1 cell extracts (Fig 1). These species might correspond to the molecular mass of the
hypoglycosylated protein or could correspond to degradation products; although Kasumi-1
cells were cultured in the presence of an inhibitor of proprotein convertase (PC), which expres-
sion in human cancer cells increases both proliferation and invasive ability [15]. The presence
of lower molecular mass α-Dg species might also suggest a failure in the posttranslational pro-
cessing of dystroglycan, rather than in the synthesis of α-dystroglycan itself. Therefore we can
not discard the presence of mutations in one of the seven glycosyltransferases or glycosyltrans-
ferase-like genes, that have been found to be involved in α-Dg functional glycosylation [6].
Enrichment of cell extracts with WGA and the use of IIH6C4 antibody let us determine the
presence of the full-glycosylated α-Dg 150 kDa band.
Our flow cytometry analysis showed a reduced detection of α-Dg, based on its loss of reac-
tivity to antibodies that recognize the laminin binding glycoepitope of α-Dg (IIH6C4 and
VIA4-1) specifically in dKasumi-1 cells. This diminution was less evident for the reactivity
observed with IIH6C4 and absent for the α-Dg core protein (cranin antibody).
Therefore, the diminutions detected are attributable to a specific reduction of laminin-bind-
ing glycan formation on α-Dg [16] and are inherent to the differentiation process. This hypo-
glycosylation is likely to reduce the functionality of α-Dg as a receptor for its known
extracellular matrix proteins, including laminin, neurexin, and agrin [17]. However, our over-
lay assays, showed a residual laminin-binding detected from α-Dg 150 kDa specie. It has been
reported that laminin-1 binding pattern is retained after enzymatic deglycosylation [18], this
might suggest that Kasumi-1 cells might have additional laminin binding epitopes, which are
less susceptible to deglycosylations. It is important to consider the existence of integrins, that
have been reported to function as laminin receptors [19].
In vitro differentiated macrophages and myelomonocytic cell lines showed down-regulation
of adhesion molecules after TPA treatment [20]. We hypothesised that under physiological
conditions, during macrophage-like generation cells Dg is also downregulated, facilitating cell
recruitment to solid tissues.
The presence of a nuclear localisation sequence (NLS) has been described in β-Dg [21],
therefore the presence of β-Dg and specially β-DgPY892 in the nucleus of dKasumi-1 cells
might indicate its potential role as a scaffold during the differentiation process, which is charac-
terised for the change of nuclear shape from rounded to lobular. The role of dystroglycan as an
organiser of nuclear architecture has been documented; as well as the interaction of β-Dg with
other nuclear proteins including emerin and lamin B1 that could contribute to a role for modu-
lation of transcriptionally active regions in the nucleus [22,23].
Recently, it has been described that full-length β-Dg (43 kDa) was the predominant specie
found in the nuclear fraction, whereas for phosphorylated β-Dg the 31 kDa transmembrane
and cytoplasmic fragment was more prominent in the nucleus. Our cell fractioning assays,
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showed that the 43 and 38 kDa β-Dg proteins were mainly located in the cytoplasm fraction,
while a 50 kDa specie was observed in the nuclear fraction as has been reported for prostate tis-
sues [23]. According to our results, Dg species distribution in different cell compartments
should play a particular role depending on its physiological stage, the tissue or even on the cell
lineage if we compare with HL-60 cells (promyelocytic leukaemia cell line) [9].
The Kasumi-1 cell line is a model system of Acute Myeloid Leukaemia with t(8;21) translo-
cation, and the corresponding functional consequences of the AML1-ETO fusion oncogene on
myeloid differentiation [24]. Nevertheless leukemogenesis involves multiple genetic changes
that impair hematopoietic differentiation, it is believed that signalling by tyrosine kinases other
than KIT may be responsible for proliferative and/or survival advantage in Kasumi-1 cells [25].
It could be therefore, that the activation of other tyrosine kinases during the differentiation
process, such as Src [26,27], could lead to the increased levels of phosphorylated dystroglycan
observed.
The knockdown of Dg slows dKasumi-1 cells movement as well as the maintenance of a
more rounded shape and altered filopodia extension compared to control cells (Fig 6). Similar
phenotypes have also been described for oligodendrocytes and HL-60 cells [9,28]; in addition,
alteration in filopodia number and length also affect concomitant cell motility and phagocytic
capabilities. Dystroglycan has been proposed to be important for the maturation of adhesions
into fibrillar adhesions and therefore in long-term adhesion and migration cells [29]. Our
results demonstrate that a direct consequence of the reduction in dystroglycan have an effect
on actin cytoskeletal dynamics, through its binding to actin, and also modulating the actin reg-
ulatory machinery through RhoGDI [4,30,31].
Treatment of cells with cytochalasin D demonstrated that the functions affected by dystro-
glycan depletion depend on actin cytoskeleton such as phagocytosis, migration, number and
length of filopodia, according to the experiments showed in Fig 7.
Kasumi-1 cells as an in vitro biological model mimic the acute myeloblastic leukaemia and
although they only recapitulate parts of the disease, they are critical to discern mechanisms of
normal differentiation process and they help to explain the leukaemia progression in which
dystroglycans play an important role.
Conclusion
Our findings strongly suggest the participation of dystroglycan as a scaffolding protein that is
part of actin-based structures, and actively participates in filopodia extrusion, phagocytosis,
and migration that were evident in Kasumi-1 cells differentiated to macrophage-like cells.
Supporting Information
S1 Fig. Specific contribution of phosphorylated dystroglycan in Kasumi-1 cells. (A) Per-
centage of the specific contribution of β-DgPY892 (31 kDa band) in relation to the rest of the
proteins detected with the respective antibody in nd-Kasumi-1 cells. B. Percentage of the Spe-
cific contribution of β-DgPY892 (31 kDa band) in relation to the rest of the proteins detected
with the respective antibody in dKasumi-1 cells.
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